SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Digital isometric background red warning alert icon and decreasing stock market graph, economic crisis, financial risk, and market crash.
Vaccines
Moderna’s stock rides hantavirus fears as spotlight returns to infectious disease platform
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
May 20, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Stand out from the crowd and different creative idea concepts , Longest light ladder glowing and aiming high to goal target among other short ladders on green background with shadows . 3D rendering.
Drug Development
Beam one-ups Wave as both show promise of genetic editing for AATD
While both Beam Therapeutics and Wave Life Sciences touted notable biomarker benefits for their respective alpha-1 antitrypsin deficiency assets, analysts said that Beam might have the efficacy advantage as Wave’s drug hits an efficacy “ceiling.”
May 20, 2026
 · 
2 min read
 · 
Tristan Manalac
Crawling manager or businessman tramped by big foot. Close-up view of feet on a tired and sweaty male worker's back . Flat vector illustration template.
Immunology and inflammation
AbbVie’s new immunology standard-bearer Skyrizi kneels to UCB’s Bimzelx in psoriatic arthritis
UCB’s Bimzelx elicited significantly stronger joint relief at 16 weeks than AbbVie’s Skyrizi in a Phase 3 head-to-head study of psoriatic arthritis.
May 20, 2026
 · 
2 min read
 · 
Tristan Manalac
FDA
FDA’s absent leaders, the millions pharma CEOs make, and pancreatic cancer’s momentum
Fallout from the resignation of FDA Commissioner Marty Makary continues as several other senior regulators are removed from their posts; pharma’s top paid CEOs make up to 358 times more than their employees; Revolution Medicine’s pancreatic cancer results highlight movement in the deadly disease space; more.
May 20, 2026
 · 
1 min read
 · 
Jef Akst
Businessman finds himself difficult to make decision because of too many directions or choices to choose. Cute character vector illustration, outline, thin line art, hand drawn sketch, black and white ink style.
Antibody-drug conjugate (ADC)
Daiichi emerges from bruising 2 years with vision for cracking cancer’s big leagues
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
May 20, 2026
 · 
4 min read
 · 
Nick Paul Taylor
Professional hand serving growing financial bar chart on a silver platter to a businessman illustrating wealth management success and strategic investment growth opportunities
Business
J&J’s Duato makes 358 times his median employee; Vertex CEO makes just 80 times
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
May 20, 2026
 · 
1 min read
 · 
Annalee Armstrong
sprint start in track and field in blurred motion
Rare diseases
Relay doubles the bar, outpacing Novartis with a 60% response in rare disease
Analysts are extremely encouraged by Phase 2 trial results for Relay Therapeutics’ PI3KA inhibitor in treating vascular malformations (VM), prompting the biotech to eye a potential path to accelerated approval.
May 19, 2026
 · 
2 min read
 · 
Gabrielle Masson
Illustration showing people forming an arrow versus large arrow
Job Trends
Takeda cuts send layoffs soaring in May, rising year over year
Far fewer companies are letting employees go so far in 2026 compared to 2025, but the number of people affected is trending up, especially this month, according to BioSpace tallies.
May 19, 2026
 · 
4 min read
 · 
Angela Gabriel
Balloon and missed bow spears arround . Target audience and marketing concept . This is a 3d render illustration .
Rare diseases
BioMarin suffers another blow to rare disease portfolio in Phase 3 flop
BioMarin’s investigational therapy failed to elicit clinical improvements in patients with ENPP1 deficiency, while also missing key secondary endpoints of rickets severity and growth.
May 19, 2026
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS